Tvardi Therapeutics Inc [TVRD] stock prices are down -5.14% to $6.64 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The TVRD shares have lost -83.36% over the last week, with a monthly amount drifted -80.37%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tvardi Therapeutics Inc [NASDAQ: TVRD] stock has seen the most recent analyst activity on October 14, 2025, when Raymond James downgraded its rating to a Mkt Perform. Previously, Barclays downgraded its rating to Equal Weight on October 14, 2025, and kept the price target unchanged to $5. On October 13, 2025, Barclays initiated with a Overweight rating and assigned a price target of $61 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $4 on October 13, 2025. Cantor Fitzgerald downgraded its rating to a Neutral. Raymond James started tracking with a Outperform rating for this stock on July 14, 2025, and assigned it a price target of $62. In a note dated July 11, 2025, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $52 on this stock.
The stock price of Tvardi Therapeutics Inc [TVRD] has been fluctuating between $5.65 and $43.65 over the past year. Currently, Wall Street analysts expect the stock to reach $4.5 within the next 12 months. Tvardi Therapeutics Inc [NASDAQ: TVRD] shares were valued at $6.64 at the most recent close of the market. An investor can expect a potential drop of -32.23% based on the average TVRD price forecast.
Analyzing the TVRD fundamentals
The Tvardi Therapeutics Inc [NASDAQ:TVRD] reported sales of 6.58M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -3.58%, Pretax Profit Margin comes in at -3.24%, and Net Profit Margin reading is -3.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.48, Equity is 1.43 and Total Capital is -0.71. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Tvardi Therapeutics Inc [NASDAQ:TVRD]’s Current Ratio is 4.04. On the other hand, the Quick Ratio is 4.04, and the Cash Ratio is 1.93. Considering the valuation of this stock, the price to sales ratio is 9.46, the price to book ratio is 1.89.
Transactions by insiders
Recent insider trading involved Posner Christopher, PRESIDENT AND CEO, that happened on Feb 28 ’25 when 583.0 shares were sold. SEC’Y; CHIEF COMPLIANCE & G.C., Terrillion Scott completed a deal on Feb 28 ’25 to sell 163.0 shares. Meanwhile, PRESIDENT AND CEO Posner Christopher sold 372.0 shares on Feb 04 ’25.
